期刊文献+

紫杉醇诱导喉咽癌耐药细胞株的生物学特性 被引量:1

Biological characteristics of FaDu/T cells of hypopharyngeal carcinoma induced by Taxol
在线阅读 下载PDF
导出
摘要 目的研究人喉咽癌细胞株FaDu与其耐药株FaDu/T在生物学特性方面的异同及内在联系。方法以喉咽癌FaDu细胞为亲本,通过紫杉醇(Taxol)递增法筛选出其耐药细胞株FaDu/T。MTT法检测其耐药性,流式细胞术检测其周期,吖啶橙和Hoechest 33342/PI染色法检测细胞凋亡情况;RT-PCR和Western blot检测多药耐药、凋亡相关基因。结果与FaDu细胞相比,FaDu/T细胞具有以下特点:①生长缓慢;②多药耐药性增强;③处于G0/G1期较多,而G2/M和S期较少,凋亡比例无明显差别;④耐药基因ABCB1表达增加;⑤抗凋亡蛋白Bcl-2表达增加,凋亡蛋白Bax、Caspase-3表达下降。结论 FaDu/T细胞中耐药及抗凋亡蛋白ABCB1、Bcl-2的高表达是肿瘤细胞化疗抵抗的关键原因,肿瘤细胞各生物学特性的内在联系有待进一步研究。 OBJECTIVE To investigate the different or similar characteristics between the hypopharyngeal carcinoma cell line(FaDu cells)and the multidrug resistance(MDR)cell lines(FaDu/T)induced by Taxol.METHODS Human FaDu cells were exposed in stepwise escalating concentration of Taxol until the resistant cell line was formed.The drug resistance was investigated by methyl-thiazolyl-tetrazolium(MTT)assay.The cell apoptosis was measured by staining cells with acridine orange(AO),Ho.33342 and PI staining.Meanwhile,the cell cycle distribution was quantified through flow cytometry.Reverse Transcription Polymerase Chain Reaction(RT-PCR)was conducted to detect mRNA levels of the drug resistance genes ABCB1 and apoptosis related genes Bax,Bcl-2,Caspase-3.The proteins levels were detected through Western blot.RESULTS Compared with parents FaDu cells,the drug resistance cells of FaDu/T had the biological characteristics as follows: ①They had a lower growth velocity;②Their mutidrug resistance ability was increased;③The percentage of cells in G0/G1 phases was increased while that in G2/M and S phase decreased,but the proportion of apoptosis cells had no prominent difference;④The expression of ABCB1 gene increased significantly;⑤The anti-apoptotic protein Bcl-2 increased prominently,while the apoptotic protein,Caspase-3 and Bax,decreased.CONCLUSION The high expression of ABCB1,Bcl-2 may be the critical reason of the chemotherapy resistance in FaDu/T;but the internal connection among various biological characteristics of tumor cells is worth to be further investigeated.
出处 《中国耳鼻咽喉头颈外科》 北大核心 2011年第12期658-662,共5页 Chinese Archives of Otolaryngology-Head and Neck Surgery
关键词 下咽肿瘤 细胞 培养的 多药耐药相关蛋白质类 细胞凋亡 流式细胞术 Hypopharyngeal Neoplasms Cells Cultured Multidrug Resistance-Associated Proteins Apoptosis Flow Cytometry
作者简介 第一作者简介及通讯:马聚珂,男,河南人,在读医学硕士,主要从事头颈肿瘤的研究。Email:majuke99@163.com 通讯作者:徐伟(Email:xwhns@yahoo.com.cn)
  • 相关文献

参考文献12

  • 1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008.CA Cancer J Clin,2008,58:71-96.
  • 2Wang SJ,Wong G,de Heer AM,et al.CD44 variantisoforms in head and neck squamous cell carcinomaprogression.Laryngoscope,2009,119:1518-1530.
  • 3奚艳,隋军,李晓江,孙瑞梅.rAd-p53联合放化疗治疗晚期头颈部鳞状细胞癌[J].中国耳鼻咽喉头颈外科,2009,16(2):101-102. 被引量:1
  • 4Clark JI,Hofmeister C,Choudhury A,et al.Phase IIevaluation of paclitaxel in combination with carboplatin inadvanced head and neck carcinoma.Cancer,2001,92:2334-2340.
  • 5Rowinsky EK,Donehower RC,Jones RJ,et al.Microtubulechanges and cyto-toxicity in leukemic cell lines treated withTaxol.Cancer Res,1988,48:4093-4100.
  • 6Liang Y,Meleady P,Cleary I,et al.Selection withmelphalan or paclitaxel(Taxol)yields variants with differentpatterns of multidrug resistance,integrin expression and invitro invasiveness.Eur J Cancer,2001,37:1041-1052.
  • 7于亮,李会政,逯素梅,刘闻闻,田家军,李建峰,王海波,徐伟.TWIST在紫杉醇诱导喉癌Hep-2细胞系凋亡中的作用研究[J].中华耳鼻咽喉头颈外科杂志,2009,44(9):772-776. 被引量:2
  • 8Lu KH,Lue KH,Chou MC,et al.Paclitaxel inducesapoptosis via caspase-3 activation in human osteogenicsarcoma cells(U-2 OS).J Orthop Res,2005,23:988-994.
  • 9张健梅,文姝,李洁,彭园园.三氧化二砷与紫杉醇联合诱导Hep-2细胞凋亡的体外研究[J].中国耳鼻咽喉头颈外科,2011,18(4):196-199. 被引量:4
  • 10Lagas JS,Vlaming ML,van Tellingen O,et al.Multidrugresistance protein 2 is an important determinant of paclitaxelpharmacokinetics.Clin Cancer Res,2006,12:6125-6132.

二级参考文献29

  • 1张珊文,肖绍文,刘长清,孙艳,苏星,李东明,徐刚,蔡勇,朱广迎,徐博,吕有勇.重组人p53腺病毒注射液联合放射线治疗头颈鳞癌的Ⅱ期临床试验[J].中华医学杂志,2003,83(23):2023-2028. 被引量:70
  • 2韩德民,黄志刚,张伟,于振坤,王琪,倪鑫,陈晓红,潘锦华,王鸿.重组人p53腺病毒注射液治疗喉癌的Ⅰ期临床试验及追踪观察[J].中华医学杂志,2003,83(23):2029-2032. 被引量:60
  • 3陈传本,潘建基,徐鹭英.重组人p53腺病毒注射液结合放射治疗鼻咽癌Ⅱ期临床试验观察[J].中华医学杂志,2003,83(23):2033-2035. 被引量:52
  • 4尤学芬,谢玉娟,丁润生,陆德炎,姚登福.Bax基因在紫杉醇诱导HL-60细胞凋亡过程中作用的研究[J].交通医学,2007,21(2):119-120. 被引量:1
  • 5Tishler RB, Busse PM, Norris CM Jr, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys, 1999,43: 1001-1008.
  • 6I-Iaddad R, Tishler RB, Norris CM, et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality" treatment. Oncologist,2003 ,8 :35-44.
  • 7Haraf D J, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Chn Cancer Res, 2003, 9:5936-5943.
  • 8Yang X, Chang HY, Baltimore D. Autoproteolytic activation of pro-caspases by oligomerization. Mol Cell, 1998, 1:319-325.
  • 9Cheng GZ, Zhang WZ, Wang LH, et al. Regulation of cancer cell survival migration, and invasion by TWIST: AKT2 come to interplay. Cancer Res, 2008,68: 957-960.
  • 10Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol, 2007, 31:277-283.

共引文献4

同被引文献14

  • 1Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer. J Pathol, 2011, 223: 102-115.
  • 2HuiAB, Lenarduzzi M, Krushel T, et al. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res, 2010, 16: 1129-1139.
  • 3Chang SS, Jiang WW, Smith I, et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer, 2008, 123: 2791-2797.
  • 4Ramdas L, Giri U, Ashorn CL, et al. miRNAexpression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck, 2009, 31: 642-654.
  • 5Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116: 281-297.
  • 6Kluiver J, van den Berg A, de Jong D, et al. Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene, 2007, 26: 3769-3776.
  • 7Pedersen IM, Otero D, Kao E, etal. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med, 2009, 1: 288-295.
  • 8Greither T, Grochola LF, UdelnowA, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatictumors is associated with poorer survival. Int J Cancer, 2010, 126: 73-80.
  • 9Chen HC, Chen GH, Chen YH, etal. MicroRNAderegulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer, 2009, 100: 1002-1011.
  • 10Tam W, Dahlberg JE. miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer, 2006, 45: 211- 212.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部